Epilepsy

Finkel discussed his new role at St. Jude Children’s Research Hospital, where he'll head up the new Center for Experimental Neurotherapeutics.

The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.

The professor of neurology at NYU Langone gives her input on those who are nervous to take hospital trips, as well as the protocol for patients with neurological disorders as COVID-19 slows down.

Data suggest that discrepancies in genetic testing for epilepsy warrant second opinions for interpretations as well as clinical reports that become part of a patient’s medical record following a second opinion.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.

The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.

The director of pediatric epilepsy and professor of neurology at Mayo Clinic details the rampant acceleration of telemedicine and how her practice is adjusting to the COVID-19 pandemic.

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.

The professor of neurology at NYU Langone discussed the risk of COVID-19 in patients with neurological disorders.

Neurology News Network for the week ending May 2.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 1, 2020.

An emphasis on at-home care as well as reducing the risk of seizure exacerbation are among a list of notable recommendations to help optimize clinical care for patients with epilepsy amidst the COVID-19 pandemic.

The professor of neurology at NYU Langone detailed the neurologic symptoms that have been observed in patients with COVID-19.

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

Retrospectively analysis data suggest that while the majority of epileptics have no significant worsening in bone mineral density, they maintain an amplified risk of suffering major osteoporotic fractures.